m



"Express Mail" mailing label number EL 856 154 441 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on

Printed: Nancy Ramos



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)

Commissioner for Patents **Box Patent Application** Washington, D.C. 20231

Dear Sir:

This is a request for filing a DIVISIONAL application under 37 CFR 1.53(b) of pending prior application Serial No.09/295,055, filed on April 20, 1999, entitled NEW ANNEXIN BINDING PROTEIN.

- 1. X Enclosed is a specification corresponding to the prior application, U. S. Application Serial No.09/295,055 filed April 20, 1999, including the oath or declaration as originally signed. The specification does not contain any subject matter that would have been new matter in the prior application.
- With regard to the requirement of 37 CFR 1.821(e) which requires that a copy of the Sequence Listing in computer readable form (CRF) be submitted, Applicants state that the paper copy of the Sequence Listing for the instant divisional application is identical with the computer readable form filed with Serial No. 09/295,055, filed April 20, 1999, to which priority is claimed. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed with U.S. Application Serial No. 09/295,055 as the computer readable form for the instant divisional application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant divisional application.
- 3. \_\_\_\_ before calculating the filing fee, without prejudice or disclaimer. Applicants submit that these claims were included in the application as filed in the interest of providing notice to the public of certain specific subject matter intended to be claimed, and are being canceled at this time in the interest of reducing filing costs. Applicants expressly state that these claims are not being canceled for reasons related to patentability, and are in fact fully supported by the specification as filed. Applicants expressly reserve the right to reinstate these claims or to add other claims during prosecution of this application or a continuation or divisional application. Applicants expressly do not disclaim the subject matter of any invention disclosed herein which is not set forth in the instantly filed claims.
- The inventor(s) of the invention being claimed in this application is (are): Jennifer L. Hillman, Neil C. Corley, and Purvi Shah.

- 5. X In accordance with 37 CFR 1.63(d) a copy of the originally signed declaration showing applicants' signatures as filed on December 19, 1997 is enclosed.
- 6. \_\_\_ Amend the specification by inserting after the title: "This application is a divisional application of U.S. application serial number 09/295,055, filedApril 20, 1999, all of which applications and patents are hereby incorporated herein by reference."
- 7. X The filing fee is calculated below:

Claims	Number Filed	Minus	Number Extra	Small	Than	Basic Fee \$710.00
Total Claims	19	-20	0	x \$18	0	\$ 0
Indep. Claims	1	-3	0	x \$80	0	\$0
Multiple Dependent Claim(s), if any + \$270						\$

TOTAL FILING FEE \$ 710.00

- 8. \_\_\_ An extension of time in the above-named prior application has been requested and the fees therefore have been authorized in said application.
- 9. X Please charge Deposit Account No. <u>09-0108</u> in the amount of \$ 710.00

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. **09-0108**.

A duplicate copy of this Request is enclosed.

- 10. X New formal drawings are enclosed.
- 11. X The prior application is assigned of record to Incyte Pharmaceuticals, Inc, recorded on December 24, 1997, at reel 8879/frame 0561.
- 12. \_\_\_ A preliminary amendment is enclosed.
- 13. X Also enclosed Information Disclosure Statement (2 pp., in duplicate); List of References Cited by Applicants (PTO 1449 form) 1 pg.).
- 14. X The power of attorney of the prior application is to:

Lucy J. Billings	Reg. No. 36,749
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Richard C. Ekstrom	Reg. No. 37,027
Barrie D. Greene	Reg. No. 46,740
Matthew R. Kaser	Reg. No. 44,817
Lynn E. Murry	Reg. No. 42,918
Shirley A. Recipon	Reg. No. 47,016
Susan K. Sather	Reg. No. 44,316

Michelle M. Stempien	Reg. No. 41,327		
David G. Streeter	Reg. No. 43,168		
Stephen Todd	Reg. No. 47,139		
Christopher Turner	Reg. No. 45,167		
Peng Ben Wang	Reg. No. 41,420		

- X A copy of a Certificate Under 3.73(b), Revocation of Power of Attorney and Appointment of New Attorneys filed in application Serial No. 09/295,055 is enclosed.
- a. \_\_ An associate power of attorney is attached.
- b. \_\_\_ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. X Address all future correspondence to:

## INCYTE GENOMICS, INC. PATENT DEPARTMENT 3160 Porter Drive

Palo Alto, California 94304 Phone: (650) 855-0555, Fax: (650) 845-4166

Date: March 13, 2001 By: David S. Struck

David G. Streeter, Ph.D. Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

\_\_\_ Inventor(s)

\_\_\_\_ Assignee of complete interest

X Attorney or agent of record

\_\_\_ Filed under 37 CFR 1.34(a)

Registration number if acting under 37 CFR 1.34(a)